Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 328 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | April 14, 2014

Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?

Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?

Investing | April 12, 2014

This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere

A surprise buyout, MannKind's sanguine PDUFA update regarding Afrezza, and three positive clinical studies, mark this week's top biotech stories.

Investing | April 08, 2014

The Worst Biotech Failures of the Week

See which companies suffered the worst clinical setbacks in the week ending April 4.

Investing | April 02, 2014

Biggest Clinical Wins of the Week: Large-Cap Edition

See which big biotech and pharmaceutical companies got the best clinical results for the week ending March 28.

Investing | April 02, 2014

Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam

MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.

Investing | March 29, 2014

Finding a Niche for Celgene's Otezla

Celgene's Otezla isn't going to beat antiinflamatory drugs from AbbVie, Johnson & Johnson, and Amgen on efficacy, but the biotech can still find a niche for its new psoriatic arthritis drug.

Investing | March 28, 2014

This Rapidly Evolving New Cholesterol Treatment Pathway Demands Your Attention

High cholesterol therapies could be ready to take a gigantic leap forward with the introduction of this new class of drugs.

Investing | March 27, 2014

Can AbbVie's Legacy Products Deliver Further Growth?

AbbVie is spending more than 16% of annual sales to develop new drugs that will lesson the drug maker's dependence on the rheumatoid arthritis drug Humira. Fortunately, the Chicago-based drug manufacturer has a stable of off-patent, legacy drugs that contribute sizable sales to this R&D effort.

Investing | March 26, 2014

Watch Out AbbVie, Here Comes Celgene

AbbVie's (ABBV) Humira is facing new competition in psoriatic arthritis following the FDA's recent approval of Celgene's (CELG) Otezla.

Investing | March 25, 2014

Last Week's BioPharma R&D Winners

See which companies scored big in the clinic.

Results 1 - 10 of 328 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology